Elisabetta Terruzzi
About
Elisabetta Terruzzi is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine.
According to data from OpenAlex, Elisabetta Terruzzi has authored 20 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Public Health, Environmental and Occupational Health and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Elisabetta Terruzzi's work include Acute Lymphoblastic Leukemia research (9 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). Elisabetta Terruzzi is often cited by papers focused on Acute Lymphoblastic Leukemia research (9 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). Elisabetta Terruzzi collaborates with scholars based in Italy, Germany and United States. Elisabetta Terruzzi's co-authors include Enrico Maria Pogliani, Alessandro Rambaldi, Matteo Parma, Emanuele Angelucci, Claudio Romani, Daniele Mattei, Giuseppe Rossi, Tamara Intermesoli, Alessandro Levis and Elena Oldani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Elisabetta Terruzzi
19 papers receiving 419 citations
Peers
Elisabetta Terruzzi
Woo‐Sung Min South Korea
B-S Cho South Korea
K-S Eom South Korea
Saverio Ladogana Italy
Gianna Maria D’Elia Italy
C-K Min South Korea
Fabiana Ostronoff United States
Natacha Maillard France
HM Lazarus United States
Chantal S. Leger Canada
Citations per year, relative to Elisabetta Terruzzi Elisabetta Terruzzi (= 1×)
peers
Woo‐Sung Min
Countries citing papers authored by Elisabetta Terruzzi
Since
Specialization
Citations
This map shows the geographic impact of Elisabetta Terruzzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabetta Terruzzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabetta Terruzzi more than expected).
Fields of papers citing papers by Elisabetta Terruzzi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Elisabetta Terruzzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabetta Terruzzi. The network helps show where Elisabetta Terruzzi may publish in the future.
Co-authorship network of co-authors of Elisabetta Terruzzi
This figure shows the co-authorship network connecting the top 25 collaborators of Elisabetta Terruzzi. A scholar is included among the top collaborators of Elisabetta Terruzzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabetta Terruzzi. Elisabetta Terruzzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Aroldi, Andrea, Federica Colombo, Giovanni Grillo, et al.. (2023). Evaluating the performance of large language models in haematopoietic stem cell transplantation decision‐making. British Journal of Haematology. 204(4). 1523–1528.
2.
Ramazzotti, Daniele, Andrea Aroldi, Federica Colombo, et al.. (2023). Evaluating the Performance of Large Language Models in Hematopoietic Stem Cell Transplantation Decision Making. Blood. 142(Supplement 1). 3726–3726.
3.
Aroldi, Andrea, Mario Mauri, Matteo Parma, et al.. (2021). CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma. Blood. 138(Supplement 1). 2276–2276.
4.
Choe, Hannah, Nirav N. Shah, Patrice Chevallier, et al.. (2020). A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119). Blood. 136(Supplement 1). 50–51.
5.
Sorà, Federica, Carmen Di Grazia, Patrizia Chiusolo, et al.. (2019). Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. Biology of Blood and Marrow Transplantation. 26(4). 698–703.
6.
Dodero, Anna, Francesca Patriarca, Giuseppe Milone, et al.. (2017). Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Biology of Blood and Marrow Transplantation. 23(7). 1102–1109.
7.
Parma, Matteo, A Colombo, Federica Mottadelli, et al.. (2015). GOOD OUTCOME FOR VERY HIGH RISK ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA CARRYING GENETIC ABNORMALITIES t(4;11)(q21;q23) or t(9;22)(q34;q11), IF PROMPTLY SUBMITTED TO ALLOGENEIC TRANSPLANTATION, AFTER OBTAINING A GOOD MOLECULAR REMISSION.. Mediterranean Journal of Hematology and Infectious Diseases. 7(1). e2015041–e2015041.
8.
Intermesoli, Tamara, Alessandro Rambaldi, Giuseppe Rossi, et al.. (2013). High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 98(11). 1718–1725.
9.
Intermesoli, Tamara, Alessandro Rambaldi, Chiara Cattaneo, et al.. (2012). High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program. Blood. 120(21). 1494–1494.
10.
Bassan, Renato, Giuseppe Rossi, Enrico Maria Pogliani, et al.. (2010). Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00. Journal of Clinical Oncology. 28(22). 3644–3652.
11.
Perseghin, Paolo, Elisabetta Terruzzi, Maria Dassi, et al.. (2009). Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfusion and Apheresis Science. 41(1). 33–37.
12.
Bassan, R, Tamara Intermesoli, Elena Oldani, et al.. (2008). Short-course imatinib (IM) added to chemotherapy improves early but not long-term outcome in adult Ph/BCR-ABL+ acute lymphoblastic leukemia (ALL) : 5-year follow-up results of study NILG-09. Haematologica. 93. 366–367.
13.
Cavattoni, Irene, Enrico Morello, Elena Oldani, et al.. (2008). Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: An Update of the Northern Italy Leukemia Group (NILG) Experience. Blood. 112(11). 4385–4385.
14.
Musto, Pellegrino, Potito Rosario Scalzulli, Elisabetta Terruzzi, et al.. (2007). Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: Case-control study in patients with multiple myeloma and review of the literature. Leukemia Research. 31(11). 1487–1493.
15.
Elli, Elena Maria, Matteo Parma, Paolo Perseghin, et al.. (2007). Successful treatment with T depleted autologous peripheral blood stem cell transplantation of refractory chronic autoimmune thrombocytopenic purpura. Haematologica. 92(1). e7–e8.
16.
Cavattoni, Irene, Enrico Morello, Michael Mian, et al.. (2006). Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: The Northern Italy Leukemia Group (NILG) Experience.. Blood. 108(11). 5380–5380.
17.
Rossini, Fausto, Elisabetta Terruzzi, Simona Cammarota, et al.. (2005). Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transplant Infectious Disease. 7(3-4). 122–125.
18.
Rossini, Fausto, et al.. (2004). Long‐term follow‐up of patients with intermediate or high‐grade non‐Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone. Cancer. 100(2). 350–355.
19.
Rossini, Fausto, Elisabetta Terruzzi, Luisa Verga, et al.. (2004). A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Supportive Care in Cancer. 13(6). 387–392.
20.
Torgano, Giuseppe, C. Mandelli, C. Abbiati, et al.. (2002). Gastroduodenal lesions in polycythaemia vera: frequency and role ofHelicobacter pylori. British Journal of Haematology. 117(1). 198–202.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Woo‐Sung Min Breakdown of academic impact, for papers by B-S Cho Breakdown of academic impact, for papers by K-S Eom Breakdown of academic impact, for papers by Saverio Ladogana Breakdown of academic impact, for papers by Gianna Maria D’Elia Breakdown of academic impact, for papers by C-K Min Breakdown of academic impact, for papers by Fabiana Ostronoff Breakdown of academic impact, for papers by Natacha Maillard Breakdown of academic impact, for papers by HM Lazarus Breakdown of academic impact, for papers by Chantal S. Leger